Compounds > etoposide
Page last updated: 2024-08-23

etoposide and zd 6474

etoposide has been researched along with zd 6474 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N1
DeRyckere, D; Gore, L; Macy, ME1
Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J1
Craveiro, RB; Dilloo, D; Ehrhardt, M; Goetz, B; Olschewski, M; Pietsch, T; Velz, J1

Trials

1 trial(s) available for etoposide and zd 6474

ArticleYear
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
    Cancer, 2017, 01-01, Volume: 123, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma

2017

Other Studies

4 other study(ies) available for etoposide and zd 6474

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine

2010
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Acute Disease; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Etoposide; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia; Methotrexate; Piperidines; Protein Kinase Inhibitors; Quinazolines; Topoisomerase II Inhibitors

2012
The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
    Oncotarget, 2017, Jul-18, Volume: 8, Issue:29

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Humans; Indazoles; Medulloblastoma; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfonamides

2017